ArticleNucleic acids research2003
A novel engineered meganuclease induces homologous recombination in yeast and mammalian cells.
Article in Nucleic acids research, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 106 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
106 citing papers in PubMed.
- Review
- Next-generation CRISPR systems and advanced delivery paradigms for precision crop improvement: a comparative case study in sugar beet (Frontiers in plant science · 2026Review
- Programmable genome engineering and gene modifications for plant biodesign.Plant communications · 2025Review
- Applications of multiplexed CRISPR-Cas for genome engineering.Experimental & molecular medicine · 2025Review
- Emerging tools in plant genome editing.Frontiers in genome editing · 2025Review
- Engineering structural variants to interrogate genome function.Nature genetics · 2024Review
- Gene Therapy for Inherited Liver Disease: To Add or to Edit.International journal of molecular sciences · 2024Review
- Current State of Human Gene Therapy: Approved Products and Vectors.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Enabling technology and core theory of synthetic biology.Science China. Life sciences · 2023Review
- Biomolecular condensates: Formation mechanisms, biological functions, and therapeutic targets.MedComm · 2023Review
- CRISPR-Cas: A robust technology for enhancing consumer-preferred commercial traits in crops.Frontiers in plant science · 2023Review
- An Overview of Genome Editing in Cardiovascular and Metabolic Diseases.Advances in experimental medicine and biology · 2023Article
- Unclasping potentials of genomics and gene editing in chickpea to fight climate change and global hunger threat.Frontiers in genetics · 2023Review
- Transgenesis and Genome Engineering: A Historical Review.Methods in molecular biology (Clifton, N.J.) · 2023Article
- Prospective Advances in Genome Editing Investigation.Advances in experimental medicine and biology · 2023Article
- Site-specific genome editing in treatment of inherited diseases: possibility, progress, and perspectives.Medical review (2021) · 2022Review
- Efficient gene targeting in soybean using Ochrobactrum haywardense-mediated delivery of a marker-free donor template.Plant physiology · 2022Article
- Off-target effects of base editors: what we know and how we can reduce it.Current genetics · 2022Review
- I-SceI and customized meganucleases-mediated genome editing in tomato and oilseed rape.Transgenic research · 2022Article
- Improvements of nuclease and nickase gene modification techniques for the treatment of genetic diseases.Frontiers in genome editing · 2022Review
46 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Homologous gene targeting is the ultimate tool for reverse genetics, but its use is often limited by low efficiency. In a number of recent studies, site- specific DNA double-strand breaks (DSBs) have been used to induce efficient gene targeting. Engineering highly specific, dedicated DNA endonucleases is the key to a wider usage of this technology. In this study, we present two novel, chimeric meganucleases, derived from homing endonucleases. The first one is able to induce recombination in yeast and mammalian cells, whereas the second cleaves a novel (chosen) DNA target site. These results are a first step toward the generation of custom endonucleases for the purpose of targeted genome engineering.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.